Leukemia and the hypercoagulable state. Pathogenic and therapeutic implications.
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D001792:Blood Platelets / Q000378:metabolism; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D005340:Fibrinogen / Q000378:metabolism; D006487:Hemostasis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy / Q000209:etiology*; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy; D011087:Polycythemia Vera / Q000097:blood / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy; D013922:Thrombocytosis / Q000188:drug therapy
D000925:Anticoagulants; D000970:Antineoplastic Agents; D005340:Fibrinogen; D006493:Heparin; D001215:Asparaginase